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ABSTRACT
The PI3K/AKT/mTOR signaling pathway has emerged as one of the most 
frequently deregulated in head and neck squamous cell carcinomas (HNSCC). Numerous 
alterations of various upstream and downstream components have been described; 
however, their prognostic significance and impact on HNSCC patient survival remains 
to be established. This was addressed using an unbiased cohort of 93 consecutive and 
homogeneous surgically treated HNSCC patients and results confirmed in 432 HNSCC 
patients. Our findings reveal the high prevalence of S6 phosphorylation, a surrogate 
marker of mTORC1 activation, in HNSCC specimens (>70%) and, more importantly, 
demonstrate its relevance on clinical outcome. Phosphorylation of ribosomal protein 
S6 on either Ser235/236 or Ser240/244 was consistently and significantly correlated 
with favorable prognosis, although with differences depending on the tumor site. 
Thus, p-S6 expression was significantly correlated with better disease-specific survival 
specifically in the subgroup of laryngeal carcinoma patients (P< 0.001). In addition, 
multivariate regression models revealed p-S6 to be an inverse and independent 
predictor of lymph-node metastasis (P= 0.004) and distant metastasis (P= 0.006). 
Taken together, this study unveils an unprecedented correlation of mTOR activation 
with improved clinical outcome in patients with laryngeal carcinomas and uncovers 
the potential of p-S6 expression as a good prognostic biomarker and an inverse 
predictor of lymph node and distant metastases. These results should be of broad 
interest as immunohistochemical detection of p-S6 may help to stratify patients and 
guide treatment decisions.
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INTRODUCTION
Head and neck squamous cell carcinoma (HNSCC) 
is the sixth most common cancer worldwide. The term 
HNSCC is applied primarily to those cancers arising from 
the squamous epithelium of the oral cavity, oropharynx, 
hypopharynx, and larynx. Patients with HNSCC have 
benefited greatly from the latest advances in surgical 
techniques, radiation therapy and chemotherapy. However, 
despite advances in local control and overall quality-of-life 
achieved with the use of combined modality therapies, the 
survival rates for HNSCC have only marginally improved 
over the past two decades [1]. Hence, novel methods of 
cancer detection and prognosis need to be developed.
HNSCC is a heterogeneous disease involving 
deregulation of multiple pathways linked to cellular 
differentiation, cell cycle control, apoptosis, angiogenesis, 
and metastasis [2]. The PI3K/AKT/mTOR signaling 
pathway has emerged as one of the most frequently altered 
in multiple cancers including HNSCC [3–5] and multiple 
upstream and downstream components such as Epidermal 
Growth Factor Receptor (EGFR), phosphatidylinositol 
3-kinase (PI3K), protein kinase B (AKT/PKB), 
phosphatase and tensin homolog (PTEN) and mammalian 
target of rapamycin (mTOR) have been found deregulated, 
making this pathway very attractive for the development 
of molecular-targeted therapies [6].
The PI3K pathway has been found genetically 
deregulated in human cancers at various levels. The 
first identified genetic mechanism of PI3K pathway 
activation was the loss of PTEN function by mutation or 
deletion, leading to the accumulation of the PI3K product 
phosphatidylinositol (3,4,5)-trisphosphate (PIP3). The 
accumulation of PIP3 activates a signaling cascade starting 
with the phosphorylation (activation) of the protein serine-
threonine kinase AKT by 3-phosphoinositide dependent 
protein kinase-1 (PDK1/PDPK1). PDK1 has been 
considered a “master kinase” that phosphorylates and is 
responsible for the activation of other ACG kinase family 
members, many of them related to cell proliferation, 
survival or the inhibition of apoptosis, including AKT1, 
2 and 3 [7].
Recent studies have reported high frequencies of 
somatic mutations in the PI3K catalytic subunit, p110α 
gene (PIK3CA), in various cancer types including 
HNSCC [8, 9]. The majority of PIK3CA mutations have 
been clustered within the helical (exon 9) and catalytic 
(exon 20) protein domains [8]. Furthermore, three hot-
spot mutations have been identified: E542K, E545K (both 
mapping in exon 9) and H1047R (in exon 20), which have 
been shown to increase PI3K oncogenic activity and to 
confer transforming properties in vitro and in vivo [10]. 
The PIK3CA mutation rates reported in HNSCC studies 
range from 2.6% to 19% [5], found to be particularly 
common in HPV-positive oropharyngeal tumors (reaching 
24-28%) [11].
Activating AKT1 mutations have also been 
described in solid tumors [12, 13]. The E17K mutation in 
the Pleckstrin homology (PH) domain of the AKT1 gene 
can result in PI3K-independent membrane recruitment 
of AKT, recapitulating the effects of the AKT8 murine 
leukemia retrovirus GAG-AKT fusion protein. E17K-
AKT1 exhibits transforming activity in vitro and in vivo, 
albeit at lower level than the myristoylated AKT [13]. A 
case of AKT1 mutation has been recently documented in a 
patient with high-risk HNSCC [14].
Nevertheless, the prognostic significance of PI3K/
AKT/mTOR pathway alterations and their impact on 
HNSCC patient survival remains to be established. 
This prompted us to perform a thorough analysis of 
PI3K/AKT/mTOR pathway components to investigate 
the mutational status of PIK3CA and AKT1 genes and 
the immunohistochemical expression of a number of 
pathway-related proteins (EGFR, PDK1, p-AKT, PTEN, 
p-S6) using a consecutive series of 93 surgically treated 
HNSCC patients, and to establish correlations with the 
clinicopathological parameters and disease outcome. The 
PI3K/AKT/mTOR pathway contains numerous putative 
therapeutic targets; however, to determine the prevalence 
and clinical relevance of molecular alterations in this 
pathway is fundamental to identify those with potential 
prognostic and therapeutic application to HNSCC patients.
RESULTS
Significance of PIK3CA and AKT1 mutations in 
HNSCC patients
The presence of the three activating hot-spot 
mutations (E542K, E545K and H1047R) in exons 9 and 
20 of the PIK3CA gene and the oncogenic E17K mutation 
in the PH domain of the AKT1 gene was analyzed in 
laryngeal and hypopharyngeal squamous cell carcinoma 
tissue specimens by mutant-enriched sequencing 
(Supplementary Figure S1). PIK3CA mutations were 
detected in 10 cases (13%); nine cases harboring only 
c.3140A>G (H1047R) mutation and one case harboring 
both H1047R and c.1624G>A (E542K). The AKT1 
c.49G>A (E17K) mutation was detected in seven cases 
(9%) and in two cases AKT1 mutation coexisted with 
PIK3CA (H1047R) mutation.
The relationships between PIK3CA c.3140A>G 
(H1047R) mutation, AKT1 c.49G>A (E17K) mutation 
and the clinicopathological variables are shown in 
Supplementary Table S1. PIK3CA (H1047R) mutation 
was more frequent in laryngeal carcinomas (20%, 8 
cases in larynx vs 6%, 2 cases in hypopharynx) and was 
significantly associated with stage I-II tumors (P = 0.002), 
and negative lymph node metastasis (P = 0.003).
In addition, PIK3CA (H1047R) mutation was 
more frequently detected in non-recurrent tumors (5 
out of 6 cases; P = 0.077) and only 1 tumor with local 
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recurrence, whereas tumors with regional recurrence 
or distant metastasis did not harbor PIK3CA (H1047R) 
mutation. Univariate Kaplan-Meier analysis showed that 
patients with PIK3CA (H1047R) mutation experienced 
a better disease-specific survival almost reaching 
statistical significance (Log-rank test, P = 0.063). Due 
to the complexity of our mutant-enriched sequencing 
methodology for routine clinical analysis, we also 
assessed the presence of PIK3CA mutations with two 
different kits used for diagnostic purposes in clinical 
laboratories (i.e. cobas® 4800 PIK3CA Mutation Test 
by Roche Molecular Diagnostics and PIK3CA Mutation 
Analysis Kit by EntroGen). While results obtained with 
both diagnostic kits perfectly matched, PIK3CA mutations 
were detected at a much lower frequency (1 positive case, 
2%) than using the mutant-enriched sequencing methods 
(10 positive cases, 13%).
On the other hand, the presence of AKT1 (E17K) 
mutation in this HNSCC series did not show influence on 
prognosis (Supplementary Table S1) or patient survival 
(Log-rank test, P = 0.427).
S6 phosphorylation is a common feature in 
HNSCC patients that correlates significantly 
with improved clinical outcome in laryngeal 
carcinomas
The activation status of the PI3K/AKT/mTOR 
pathway was investigated in our series of 93 laryngeal 
and hypopharyngeal carcinomas by analyzing the 
immunohistochemical expression of multiple upstream 
and downstream components, such as EGFR, PDK1, 
PTEN, p-AKT and p-S6. Positive EGFR expression 
was found in 16% (12/75) cases (Figure 1A and 1B) and 
showed no correlation with clinical parameters. Positive 
PDK1 expression was detected in 26 (35%) out of 75 
patients (Figure 1C and 1D). PDK1 expression did not 
correlate significantly with any of the clinicopathological 
features. Loss of PTEN expression was found in 40% 
(30/75) tumors (Figure 1E and 1F). PTEN loss tended to 
correlate inversely with lymph node involvement in this 
cohort (Fisher’s Exact test; P = 0.081). Since PTEN is an 
inhibitor of the PI3K/AKT/mTOR pathway, this supports 
an association of PTEN loss with favorable prognosis.
We also analyzed the phosphorylation status of AKT 
at Ser473 and ribosomal protein S6 at both Ser235/236 
and Ser240/244. Positive p-AKT expression was observed 
in 45% (34/75) cases (Figure 1G and 1H); however, no 
correlations with clinical data were found. Activation of 
ribosomal protein S6 through phosphorylation on either 
Serine 235/236 or Serine 240/244 was detected in 68% 
(51/75) and 77% (58/75) tumors, respectively (Figure 
1I-L). More importantly, positive p-S6 expression (in 
particular Ser235/236) was significantly correlated 
with clinicopathological parameters associated with 
better prognosis (Table 1). Thus, p-S6 (Ser235/236) 
was significantly associated with negative lymph node 
metastasis (Fisher’s Exact test; P < 0.001); smaller tumor 
size (P = 0.013); and lower disease stages (P = 0.001). 
Moreover, patients showing S6 phosphorylation on Serine 
235/236 exhibited lower risk of tumor recurrence (P = 
0.006), and significantly less distant metastasis (P = 0.003) 
and tumor-associated death (P = 0.002).
Furthermore, a multivariate regression model was 
constructed in order to evaluate the influence of the 
following molecular and clinicopathological parameters on 
lymph node involvement in an independent fashion: tumor 
size, localization, pathological grade, PTEN expression, 
PDK1 expression, PIK3CA (H1047R) mutation and S6 
phosphorylation. Hypopharyngeal localization, positive 
PTEN expression, absence of PIK3CA (H1047R) 
mutation, and negative p-S6 (Ser235/236) showed an 
independent predictive value for lymph node metastasis. 
According to these data, the risk for nodal metastasis 
was estimated to be 5.8-fold higher in patients with 
hypopharyngeal tumors (HR = 5.82; CI 95% 1.32-25.64; 
P = 0.02), 4.7-fold higher in patients with positive PTEN 
expression (HR = 4.7; CI 95% 1.17-18.78; P = 0.028), 
13.65-fold higher in patients without PIK3CA (H1047R) 
mutation (HR = 13.65; CI 95% 1.36-137.38; P = 0.026), 
and remarkably 49.6-fold higher in patients with negative 
p-S6 (Ser235/236) tumors (HR = 49.61; CI 95% 3.43-
716.11; P = 0.004).
Interestingly, using analogous multivariate models 
we found that S6 phosphorylation (Ser235/236) was 
the only significant independent predictor for distant 
metastasis. Thus, patients with negative p-S6 (Ser235/236) 
tumors exhibited 7.6-fold higher risk to develop distant 
metastasis than positive p-S6 (Ser235/236) tumors (HR = 
7.66; CI 95% 1.81-32.47; P = 0.006).
We next examined the influence of PI3K pathway 
components on patients’ survival. Univariate Kaplan-
Meier analysis showed that patients with tumors harboring 
S6 phosphorylation in either Ser235/236 or Ser240/244 
had a significantly better disease-specific survival (Log-
rank test, P < 0.001 and P = 0.002 respectively, Figure 2A 
and 2B). In addition, the results obtained from univariate 
Cox analysis are also shown in Table 2. Furthermore, 
multivariate Cox analysis was performed including tumor 
size, localization, lymph node metastasis, pathological 
grade, and p-S6 (Ser235/236) (Table 3). This model 
showed that only a negative p-S6 (Ser235/236) expression 
was a significant independent predictor of reduced disease-
specific survival (HR = 2.47; CI 95% 1.11-5.5; P = 0.026), 
and the presence of nodal metastasis was near significant 
(HR = 3.1; CI 95% 0.97-9.89; P = 0.056).
To further confirm these data, immunohistochemical 
analysis of both p-S6 (Ser235/236) and (Ser240/244) was 
extended to a larger series of HNSCC patients including 
432 additional cases from various tumor sites (oropharynx, 
larynx and hypopharynx). Analogous results were obtained 
in this extended patient cohort, confirming the relationship 
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of S6 phosphorylation with clinicopathological parameters 
associated with a better prognosis (Supplementary Table 
S2) and improved disease-specific survival (Log-rank 
test, P = 0.003 and P = 0.001, Figure 2C and 2D). The 
impact of p-S6 expression on disease course was also 
examined separately in each anatomic site, as we noted 
differences in p-S6 expression among the various tumor 
locations. Clear differences were observed on patient 
survival between the different subgroups. Specifically, 
we found that patients harboring laryngeal tumors with 
S6 phosphorylation on either Ser235/236 or Ser240/244 
exhibited a significantly improved disease-specific 
survival (Log-rank test, P = 0.002 and P < 0.001, Figure 
3A and 3B), whereas differences did not reach statistical 
significance in the subgroups of hypopharyngeal and 
oropharyngeal carcinomas (Figure 3C-3F). Nevertheless, 
p-S6 expression also tended to associate with a better 
survival in these subgroups of patients. The results from 
Univariate Cox analysis in the laryngeal subgroup also 
showed that both p-S6 (Ser235/236) and (Ser240/244) 
were strongly and significantly associated with improved 
disease-specific survival and overall survival (Table 4), 
although p-S6 expression was not found to be a significant 
independent predictor in multivariate analysis (HR = 1.24; 
CI 95% 0.65-2.32; P = 0.51 for Ser235/236, and HR = 
1.04; CI 95% 0.45-2.38; P = 0.93 for Ser240/244).
Together these data confirm the prevalence of S6 
phosphorylation and consequently mTORC1 activation in 
HNSCC tissue specimens and also its clinical relevance on 
patient prognosis and disease outcome, particularly in the 
subgroup of laryngeal carcinoma patients.
DISCUSSION
Recent advances in deep sequencing have 
uncovered the complexity and heterogeneity of the 
HNSCC oncogenome [5, 15]. Despite the high diversity 
of genetic alterations underlying each individual tumor, 
most molecular alterations converge into few commonly 
deregulated pathways [16]. The PI3K/AKT/mTOR 
signaling pathway has emerged as the most frequently 
mutated mitogenic pathway in HNSCC (31%) with 
multiple actionable targets, representing an excellent 
opportunity to develop more personalized therapeutic 
strategies [5, 16]. Nevertheless, the identification of 
clinically and biologically relevant features in this pathway 
is fundamental to define the central nodes that may be 
exploited therapeutically. Hence, using an unbiased cohort 
of consecutively and homogeneously treated (surgery) 
HNSCC patients, we conducted a comprehensive study 
to investigate the prognostic significance of multiple 
genetic and biochemical alterations in key players of 
the PI3K/AKT/mTOR pathway (i.e. PIK3CA and AKT1 
mutations and immunohistochemical expression of EGFR, 
PDK1, p-AKT, PTEN and p-S6). Collectively, our results 
suggest a positive correlation between the mTORC1 
activation and a less aggressive phenotype, resulting 
in a significantly improved survival in the subgroup of 
laryngeal carcinomas.
Figure 1: Immunohistochemical analysis of PI3K pathway proteins in HNSCC tissue specimens. Representative examples 
of negative and positive expression of EGFR A, B. PDK1 C, D. PTEN E, F. phosphorylation of AKT on Ser473 G, H. phosphorylation of 
S6 on Ser235/236 I, J. and phosphorylation of S6 on Ser240/244 K, L. Original magnification x200.
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Remarkably, our findings reveal the high prevalence 
of S6 phosphorylation, a surrogate marker of mTORC1 
activation, in HNSCC specimens (>70%) and, more 
importantly, demonstrate for the first time its relevance 
on clinical outcome: phosphorylation of ribosomal 
protein S6 on either Ser235/236 or Ser240/244 was a 
significant inverse predictor of lymph node metastasis, 
regional recurrence and distant metastasis. Consequently, 
S6 phosphorylation was also correlated with improved 
disease-specific survival in these patients, although 
the differences were only significant in the subgroup 
of laryngeal carcinomas. Hence, measurement of S6 
Table 1: Associations of p-S6 protein expression with clinicopathological findings, relapse and disease outcome
Characteristic No. p-S6(Ser235) 
expression (%)
P† p-S6(Ser240) 
expression (%)
P†
- pT classification      
 T1-T2 29 25 (86) 0.013 26 (90) 0.118
 T3 25 16 (64)  18 (72)  
 T4 21 10 (48)  14 (67)  
- pN classification      
 N0 27 26 (96) <0.001 25 (93) 0.022
 N1-3 48 25 (52)  33 (69)  
- Disease stage      
 I-II 15 15 (100) 0.001 15 (100) 0.023
 III 14 12 (86)  12 (86)  
 IV 46 24 (52)  31 (67)  
- Pathological grade      
 Well differentiated 28 22 (79) 0.308 25 (89) 0.161
 Moderately 
differentiated 33 20 (61)  23 (70)  
 Poorly differentiated 14 9 (64)  10 (71)  
- Site      
 Hypopharynx 34 20 (59) 0.142 23 (68) 0.097
 Larynx 41 31 (76)  35 (85)  
- Tumor Recurrence 
(at five years)‡ 25 21 (84) 0.006 21 (84) 0.085
 No 32 15 (47)  20 (63)  
 Yes      
- Disease status (at 
five years)
     
 Alive without 
disease 27 23 (85) 0.002 23 (85) 0.043
 Dead of index 
cancer 30 13 (43)  18 (60)  
 ___      
 Died of other causes 18 15 (83)  17 (94)  
Total Cases 75 51 (68)  58 (77)  
† Fisher’s exact test.
‡ Patients who died from causes not related to the index tumor were excluded from the recurrence analysis.
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phosphorylation by immunohistochemistry or by other 
means may help to stratify patients and/or to guide 
treatment decisions.
Activating PIK3CA (H1047R) mutation was the 
most frequently found mutation in our series (13%, 
10 cases), particularly frequent in the larynx (20%, 8 
cases). Moreover, PIK3CA (H1047R) mutation was 
associated with a better clinical outcome in laryngeal and 
hypopharyngeal carcinoma patients. Since most of these 
mutations (8/10) were present in laryngeal cancers, this 
association could be attributable to this location. In line 
with this, a recent analysis of TCGA sequencing data 
showed that PIK3CA mutations tended to associate with 
improved survival in HNSCC patients [17].
Numerous evidences have associated activating 
PIK3CA mutations with a more tumorigenic phenotype 
[18, 19]; however, contradicting results have been obtained 
when evaluating the prognostic significance of PIK3CA 
mutations in different human cancers. Thus, an association 
with favorable prognosis has been demonstrated in 
patients with breast [20] and esophageal carcinomas [21], 
whereas a poor prognosis has been reported in lung, colon 
and rectum cancer [19, 22, 23].
Nevertheless, PIK3CA (H1047R) mutation rate 
observed in our series by mutant-enriched sequencing 
could not be confirmed by PIK3CA mutation analysis 
with two different kits routinely used for diagnostic 
purposes. Thus, PIK3CA mutations were detected at a 
much lower frequency (1 positive case, 2%) than using the 
mutant-enriched sequencing methods (10 positive cases, 
13%). These differences may be attributable to a higher 
sensitivity of the mutant-enriched method (approximately 
0.25%), as we previously reported [24], questioning the 
prognostic relevance of these data, due to the low mutation 
rate observed at the sensitivity level (1-5%) of current 
routine diagnostic methods.
These results clearly indicate that despite activating 
mutations may be partially contributing, they are not a 
major driving force for the frequent PI3K/AKT/mTOR 
pathway activation detected in HNSCC. Although the 
PI3K pathway has been reported to harbor the highest 
percentage of mutations (30.5%) [5], widespread genomic 
Figure 2: mTOR activation is associated with favorable prognosis in HNSCC patients. Kaplan-Meier disease-specific 
survival curves of the 93 patients included in the study categorized by S6 phosphorylation on Ser235/236 A. and S6 phosphorylation on 
Ser240/244 B. Kaplan-Meier disease-specific survival for the extended series of 432 HNSCC patients categorized by S6 phosphorylation 
on S235/236 C. and S6 phosphorylation on Ser240/244 D. P values were estimated using the log-rank test.
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and epigenetic alterations may account for the frequent 
activation of the PI3K/AKT/mTOR axis in HNSCC. 
Various plausible mechanisms have been thoroughly 
discussed by Iglesias-Bartolome et al. [16]. In addition 
to activating PIK3CA mutations, copy number gains and 
mRNA overexpression are also frequent events in HNSCC 
(at 20% and 52%, respectively). In a previous study, we 
detected PIK3CA gene amplification in 37% fresh HNSCC 
samples, and AKT2 gene amplification in 30% tumors [3]. 
In addition, the present study also showed frequent PTEN 
loss and p-AKT in 40% and 45% cases respectively, which 
all may result in the activation of downstream targets 
such as mTOR. It is also worth noting that none of these 
upstream components individually or combined had an 
impact on patient survival in our series. Consequently, 
they are unlikely to be responsible for the good prognosis 
associated to the sustained mTORC1 activation, as 
reflected by S6 phosphorylation. Alternatively, it has also 
been demonstrated that there is a crosstalk between PI3K/
AKT/mTOR pathway and the RAS/RAF/MEK/ERK 
Table 2: Univariate Cox regression analysis for the disease-free survival (DSS) and the overall survival (OS)
Parameter 5-year DSS HR 
(95%CI)
P 5-year OS HR (95%CI) P
Localization       
 Larynx 70% 1  56% 1  
 Hypopharynx 41%
2.19 
(1.06-
4.55)
0.035 38% 1.8 (0.96-3.36) 0.06
T classification       
 T1-T2 68% 1  54% 1  
 T3-T4 50%
1.63 
(0.74-
3.55)
0.21 44% 1.2 (0.63-2.26) 0.59
N classification       
 N0 87% 1  69% 1  
 N1-3 41% 4.89 (1.7-14.1) 0.003 35% 2.7 (1.26-5.64) 0.01
Pathological 
grade
      
 G1-G2 62% 1  52% 1  
 G3 35%
2.02 
(0.89-
4.55)
0.11 31% 1.7 (0.69-3.5) 0.18
p-S6 
(Ser235/236)
      
 Positive 73% 1  60% 1  
 Negative 26%
3.93 
(1.89-
8.16)
<0.001 21% 2.6 (1.38-4.89) 0.004
p-S6 
(Ser240/244)
      
 Positive 67% 1  54% 1  
 Negative 26%
2.96 
(1.41-
6.19)
0.006 27% 2 (1.01-3.99) 0.045
HR Hazard Ratio, CI Confidence Interval
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pathway in cancers [25]. Furthermore, another interesting 
possibility of specific relevance to HNSCC is that REDD1, 
SESTRIN1 and SESTRIN2, all downstream targets of 
p53 and negative regulators of mTOR, are presumably 
disabled in more than 50% of HNSCC harboring TP53 
mutations what could result in mTOR activation in the 
absence of any other obvious genomic alteration of the 
PI3K pathway.
Various pathway activation phenotypes have been 
described in cancer and normal cells that could potentially 
explain the association with improved prognosis, 
including oncogene-induced senescence, maintenance 
of differentiation, and anti-invasive/anti-metastatic 
phenotypes [26–28]. Concordant with our in vivo data 
on HNSCC patients, these observations strongly and 
consistently reinforce that mTORC1 activation in the 
context of HNSCC may elicit anti-invasive and anti-
metastatic phenotypes in a subset of patients.
mTOR activity has been associated to increased 
cell motility and metastasis in colorectal cancer, prostate 
cancer and lymphangioleiomyomatosis (LAM)[29, 
30]. In addition, mTOR inhibition has been found to 
either decrease or promote cell migration and invasion 
depending on the cell system [29, 31, 32], thus indicating 
that mTOR activation only results in increased metastatic 
capability in a very specific cellular context. The fact that 
HNSCCs with mTORC1 activation (p-S6-positive) have a 
comparatively better survival than those with less active 
mTORC1, does not preclude the potential therapeutic 
value of PI3K/mTOR inhibitors for HNSCCs. In fact, 
extensive work has been performed defining the pathway 
may represent a viable molecular target in this tumor type. 
Rapamycin treatment has been used in different oncogenic 
HNSCCs models and seems to constitute a therapeutic 
alternative, for at least a subset of patients [16, 33–35]. 
In addition, multiple PI3K/AKT/mTOR inhibitors have 
been developed targeting different nodes of this pathway, 
mainly PI3K isoforms, AKT, mTORC1 and /or mTORC2 
complexes, which are currently into clinical trials. In 
future work, it would be of interest to investigate if 
HNSCCs with p-S6-positive phenotype are more sensitive 
to PI3K/mTOR inhibitors than p-S6-negative tumors.
The clinical impact of hyperactive mTOR depends 
on the tumor type as it has been revealed in two recent 
meta-analyses examining data from numerous previous 
studies [36, 37]. The combined message of these meta-
analyses is that hyperactive mTOR associates with worse 
prognosis in gynecological and gastrointestinal cancers; it 
is not associated with worse prognosis in breast cancer or 
even associated with good prognosis in some breast cancer 
types [38] or in lung cancer [36]; and it is inconclusive 
(due to small sample sizes) in HNSCCs and prostate 
cancers. Our results provide further evidence showing 
that mTOR activation (by means of p-S6 expression) has a 
distinct impact on patient survival depending on the tumor 
localization.
Table 3: Multivariate Cox regression analysis for the disease-free survival (DSS) and the overall survival (OS)
Parameter HR (95% CI) DSS P HR (95%CI) OS P
Localization     
 Larynx 1  1  
 Hypopharynx 1.19 (0.54-2.65) 0.66 1.16 (0.58-2.35) 0.67
T classification     
 T1-T2 1  1  
 T3-T4 1.07 (0.48-2.38) 0.88 1.17 (0.6-2.28) 0.64
N classification     
 N0 1  1  
 N1-3 3.01 (0.97-9.89) 0.056 1.99 (0.86-4.59) 0.11
Pathological grade     
 G1-G2 1  1  
 G3 1.61 (0.71-3.69) 0.25 1,42 (0.67-3.03) 0.36
p-S6 (Ser235/236)     
 Positive 1  1  
 Negative 2.47 (1.11-5.5) 0.026 2.6 (1.38-4.89) 0.003
HR Hazard Ratio, CI Confidence Interval
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In relation to the subsite-specific effect of pS6, 
although we cannot provide a precise explanation on 
the underlying mechanism of this differential effect, 
remarkably, analogous observations have been reported for 
other molecular alterations in a recent analysis of HNSCC 
genomic alterations using TCGA data [17], and also in 
previous studies from our group [39, 40]. Thus, a number 
of molecular alterations (such as Cortactin, Anoctamin 1, 
EGFR amplification or even PIK3CA mutation) have been 
shown to have a differential impact on patient survival 
specifically in the larynx. Therefore, this underscores 
that, in addition to molecular alterations, local anatomical 
circumstances also play a role in patient outcome. Further 
investigation into the biologic differences between larynx 
and other subsites should be performed.
To summarize, our study unveils an unprecedented 
correlation between mTOR activation and favorable 
prognosis and improved clinical outcome in laryngeal 
carcinoma patients, and uncovers the potential of S6 
phosphorylation as a good prognostic biomarker and an 
inverse predictor of lymph node and distant metastases. 
Activation of the PI3K/AKT/mTOR pathway is considered 
to play a crucial role in human neoplasms and so numerous 
drugs targeting this pathway have been developed and are 
currently in clinical trials [6, 41–43] including HNSCC 
(reviewed in [44]. Therefore, our results should be of 
broad interest, as immunohistochemical detection of p-S6 
may help to stratify patients and guide treatment decisions.
Figure 3: Distinctive effect of S6 phosphorylation on patients’ survival depending on the tumor site. Kaplan-Meier 
disease-specific survival curves categorized by S6 phosphorylation on Ser235/236 and S6 phosphorylation on Ser240/244 on the subgroup 
of laryngeal A, B. hypopharyngeal C, D. and oropharyngeal carcinomas E, F.
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MATERIALS AND METHODS
Patients and tissue specimens
Surgical tissue specimens from 93 patients with 
laryngeal and hypopharyngeal squamous cell carcinoma 
who underwent surgical treatment at the Hospital 
Universitario Central de Asturias were collected, in 
accordance to approved institutional review board 
guidelines. All experimental protocols were approved 
by the Institutional Ethics Committee of the Hospital 
Universitario Central de Asturias. Informed consent was 
obtained from all patients. Representative tissue sections 
were obtained from archival, formalin-fixed and paraffin-
embedded (FFPE) blocks and the histological diagnosis 
was confirmed by an experienced pathologist (AA).
This series included all patients with laryngeal 
and hypopharyngeal carcinomas consecutively treated 
between 2002 and 2005, who met the following 
criteria: a single primary tumor, microscopically clear 
surgical margins, absence of distant metastasis at the 
time of diagnosis and no treatment prior to surgery. 
Only three patients were women, the mean age was 
60 years (range 36 to 86 years). All but four patients 
(96%) were habitual tobacco and alcohol consumers. 
41 (44%) patients received postoperative radiotherapy 
(this was administered to pT4 and/or pN2-N3 patients). 
The characteristics of the patients studied and the 
Table 4: Univariate Cox regression analysis for the disease-free survival (DSS) and the overall survival (OS) in the 
laryngeal subgroup of patients
Parameter 5-year DSS HR 
(95%CI)
P 5-year OS HR (95%CI) P
T classification       
 T1-T2 88% 1  72% 1  
 T3-T4 51%
4.47 
(1.85-
10.81)
0.21 38% 2.52 (1.35-4.59) 0.003
N classification       
 N0 85% 1  72% 1  
 N1-3 33%
6.53 
(3.03-
14.08)
<0.001 28% 4.18 (2.29-7.42) <0.001
Pathological 
grade
      
 G1-G2 70% 1  59% 1  
 G3 31%
3.47 
(1.68-
7.16)
0.001 19% 2.74 (1.44-5.2) 0.002
p-S6 
(Ser235/236)
      
 Positive 76% 1  64% 1  
 Negative 38%
2.67 
(1.38-
5.17)
0.003 28% 2.27 (1.31-3.93) 0.003
p-S6 
(Ser240/244)
      
 Positive 70% 1  61% 1  
 Negative 35%
3.34 
(1.62-
6.87)
0.001 25% 2.72 (1.43-5.16) 0.002
HR Hazard Ratio, CI Confidence Interval
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clinicopathological features of their tumors (site, pT 
classification, pN classification, disease stage, and 
pathological grade) are shown in Supplementary 
Table S1. The stage of disease was determined after 
the surgical resection of the tumor according to the 
TNM system of the International Union against Cancer 
(7th Edition). The histological grade was determined 
according to the degree of differentiation of the tumor 
(Broders' classification).
The median follow-up of the whole series was 33 
months (range, 1-95 months), and the median follow-up 
of the patients alive at the last visit was 68 months (range, 
51-95 months). Data on HPV status were available for the 
whole series, as previously described [45, 46]. As HPV 
infection may be a confounding factor, two HPV-positive 
patients were excluded from all the analyses.
In addition, a large cohort of 432 homogeneous 
surgically treated HNSCC patients was selected as 
a validation series. This series included patients 
with laryngeal, oropharyngeal and hypopharyngeal 
carcinomas treated at the Hospital Universitario 
Central de Asturias between 1990 and 2009, who met 
the same inclusion criteria above-described for the 
exploratory series. All patients had a single primary 
tumor, microscopically clear surgical margins and 
received no treatment prior to surgery. Only fourteen 
patients were women, and the mean age was 59 years 
(range 33 to 86 years). All but twelve (97%) patients 
were habitual tobacco smokers and 404 were alcohol 
drinkers. The characteristics of the patients studied 
and the clinicopathological features of their tumors are 
shown in Supplementary Table S2. 244 (56%) of 432 
patients received postoperative radiotherapy. Only HPV-
negative patients were included in the analysis.
Tissue microarray construction
Five morphologically representative areas were 
selected from each individual paraffin-embedded 
tumor block: two for DNA isolation and three for the 
construction of a tissue microarray (TMA). To avoid 
cross-contamination, two punches of 2 mm diameter 
were taken first, using a new, sterile punch (Kai Europe 
GmbH, Solingen, Germany) for every tissue block, 
and stored in Eppendorf tubes at room temperature to 
be used for DNA extraction. Subsequently, three 1 mm 
tissue cylinders were taken from each of the 93 HNSCC 
to construct TMA blocks, as described previously [47]. 
In addition, each TMA also contained three cores of 
normal epithelium as an internal control. In order to 
check the histopathologic diagnosis and the adequacy 
of tissue sampling, a section from each TMA was 
stained with hematoxylin and eosin and examined by 
light microscopy. The same procedure was employed 
to construct TMA blocks from all the HNSCC patients 
included in the validation cohort.
DNA extraction and mutational analysis of 
PIK3CA and AKT1 genes
FFPE tumor cylinders were firstly deparaffinized in 
xylene and rehydrated through graded ethanol solutions. 
Subsequently, the tissue pellets were digested in lysis 
buffer containing 2 μg/μL proteinase K and the genomic 
DNA isolated using the QIAamp DNA Mini Kit (Qiagen, 
Valencia, CA) following manufacturer’s instructions.
Mutations in exons 9 and 20 of the PIK3CA gene 
and the E17K hot-spot mutation of the AKT1 gene were 
analyzed by direct genomic sequencing methods and 
confirmed by using mutant-enriched sequencing methods 
that we previously developed [48]. All PCR fragments 
were purified using ExoSAP-IT kit (Affymetrix, Santa 
Clara, CA) and sequencing was performed with ABI 
Prism 3730xl DNA analyzers by Genewiz, Inc (South 
Plainfield, NJ). Any alteration detected was further 
verified by sequencing of a second PCR product derived 
independently from the original DNA template.
PIK3CA mutations were also assessed using 
two different kits designed for diagnostic purposes i.e. 
cobas® 4800 PIK3CA Mutation Test by Roche Molecular 
Diagnostics (Branchburg, NJ) and PIK3CA Mutation 
Analysis Kit by EntroGen (Los Angeles, CA), following 
manufacturer’s protocols.
Immunohistochemistry
The HNSCC TMAs were cut into 3-μm sections 
and dried on Flex IHC microscope slides (Dako). The 
sections were deparaffinized with standard xylene and 
hydrated through graded alcohols into water. Antigen 
retrieval was performed using Envision Flex Target 
Retrieval solution, high pH (Dako) or with proteinase K 
(for EGFR). Staining was done at room temperature on 
an automatic staining workstation (Dako Autostainer Plus) 
using the Dako EnVision Flex + Visualization System 
(Dako Autostainer) and the following antibodies: EGFR 
pharmDx (TM) kit (Dako), mouse monoclonal anti-PKB 
kinase (PDK1) (E-3; Santa Cruz; sc-17765) at 1:2000 
dilution, rabbit monoclonal anti-Human phospho-Akt 
(Ser473), Phosphorylation Site Specific, (Clone 14-5; 
Dako; M3628) at 1:20 dilution, rabbit anti-phospho-S6 
Ribosomal Protein (Ser235/236) (Cell Signaling # 2211) at 
1:200 dilution, rabbit monoclonal Phospho-S6 Ribosomal 
Protein (Ser240/244) (D68F8 XP®; Cell Signaling # 
5364) at 1:200 dilution, and mouse monoclonal anti-
Human PTEN (Clone 6H2.1; Dako; M3627) at 1:50 
dilution. Counterstaining with hematoxylin was the final 
step.
The slides were viewed randomly, without clinical 
data, by two of the authors. The average intra- and inter-
observer variation was <5%. Since EGFR, PDK1 and 
PTEN staining showed a homogeneous distribution, 
a semi-quantitative scoring system based on staining 
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intensity was applied. Thus, EGFR immunostaining 
was scored as negative (0), weak (1), moderate (2) and 
strong protein expression (3) and PDK1 and PTEN were 
scored as negative (0), weak (1), strong (2) staining. For 
statistical purposes, EGFR and PDK1 staining data were 
dichotomized as negative expression (scores 0-1) versus 
positive expression (scores >1) and for PTEN score 0 was 
considered loss of PTEN expression.
Immunostaining for p-AKT and p-S6 was evaluated 
using a semi-quantitative scale (0%, <10%, 10-50%, or 
>50% positive tumor cells). For statistical analysis, staining 
data were dichotomized as negative expression (0-10% 
stained cells) versus positive expression (>10% stained 
cells), previously established as p-AKT cut-off level [49].
Statistical analyses
All the statistical analyses were performed using 
complete data sets. The experimental results distributed 
among the different clinical groups of tumors were tested 
for significance employing the Fisher’s exact test. Logistic 
regression models were constructed to evaluate the 
independent effect (Odds Ratio) of the molecular variables 
on a given clinicopathological feature. Survival curves 
were calculated using the Kaplan-Meier product limit 
estimate. Differences between survival times were analyzed 
by the log-rank method and the Hazard Ratio (with 95% 
CI) was calculated by univariate Cox regression analysis. 
Multivariate Cox proportional hazard models were used in 
a stepwise manner, and each variable was tested with the 
other factors as a co-variable. The HR with 95% CI and P 
values were reported. All tests were two-sided. The values 
of P ≤ 0.05 were considered statistically significant.
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